BioNTech (NASDAQ:BNTX) Sees Large Volume Increase - Here's Why

Key Points

• BioNTech experienced a significant trading volume increase of 227% on Friday, with approximately 3.09 million shares changing hands compared to the previous day's volume.
• Analysts have set a range of new price targets for BioNTech, with estimates varying from $112.00 to $155.00, while the average target price stands at $135.80.
• Despite reporting negative earnings per share of ($1.60) for the last quarter, BioNTech's revenue surged 102.6% year-over-year, totaling $306.46 million against expectations.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 3,089,034 shares traded hands during mid-day trading, an increase of 227% from the previous session's volume of 945,257 shares.The stock last traded at $94.56 and had previously closed at $104.31.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on BNTX shares. HC Wainwright restated a "buy" rating and issued a $136.00 target price on shares of BioNTech in a research note on Monday. Leerink Partners set a $112.00 target price on BioNTech in a research note on Monday, June 2nd. Truist Financial restated a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. reduced their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Wells Fargo & Company set a $150.00 price target on BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Price Performance

The firm has a 50-day simple moving average of $109.05 and a two-hundred day simple moving average of $104.08. The company has a market capitalization of $22.94 billion, a price-to-earnings ratio of -59.65 and a beta of 1.39. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same period in the prior year, the business posted ($3.36) earnings per share. BioNTech's revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently modified their holdings of the business. Rhenman & Partners Asset Management AB grew its position in shares of BioNTech by 0.3% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company's stock valued at $3,819,000 after acquiring an additional 120 shares during the period. Kennedy Capital Management LLC grew its position in shares of BioNTech by 0.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company's stock valued at $1,748,000 after acquiring an additional 127 shares during the period. Profund Advisors LLC grew its position in shares of BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company's stock valued at $459,000 after acquiring an additional 149 shares during the period. Probity Advisors Inc. grew its position in shares of BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after acquiring an additional 154 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. grew its position in shares of BioNTech by 2.5% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company's stock valued at $822,000 after acquiring an additional 186 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.